Cagrilintide + Semaglutide Blend 5/5mg

Cagrilintide + Semaglutide Blend – 5mg / 5mg (Lyophilized Peptide Blend)

The Cagrilintide + Semaglutide blend (also known as CAGRI + SEMA) is a dual peptide research combination consisting of Cagrilintide and Semaglutide, studied for its synergistic effects on metabolic regulation pathways. This combination is commonly explored in preclinical research focused on appetite signaling, glucose metabolism, and energy balance mechanisms.

Cagrilintide is a long-acting amylin analog, while Semaglutide is a GLP-1 receptor agonist. Together, they are researched for their complementary activity on satiety signaling and metabolic response pathways.

Product Details:

• Peptides: Cagrilintide + Semaglutide
• Ratio: 1:1 blend (5mg / 5mg total per vial)
• Form: Lyophilized powder
• Purity: See Certificate of Analysis
• Quantity: 10mg total (combined) per vial
• Storage: Store at -4°F (-20°C). After reconstitution, refrigerate at 36–46°F (2–8°C) and use within 30 days.

Potential Research Applications:

• Appetite regulation and satiety signaling studies
• Glucose metabolism and insulin response research
• Body weight regulation and energy balance models
• Combination peptide pathway interaction studies (GLP-1 + Amylin pathways)

Related Research Compounds

Researchers studying this blend often compare it with the individual compounds and related metabolic research peptides:

• Cagrilintide (CAGRI) single peptide — long-acting amylin analog research compound.
• Semaglutide (SEMA) — GLP-1 receptor agonist for metabolic research.
• Tirzepatide (TIRZ) — dual GIP/GLP-1 receptor agonist.
• Retatrutide (RETA) — triple agonist (GLP-1/GIP/glucagon) research peptide.

For laboratory research use only. Not for human or veterinary consumption.

CagriSema — Further Research Reading

The cagrilintide + semaglutide combination is studied against each component alone. Background methodology and comparative data:

• Cagrilintide (CAGRI) — the amylin analog component supplied separately.
• Semaglutide (SEMA) — the GLP-1 agonist component supplied separately.
• Semaglutide research guide — receptor mechanism and published trial data.
• Semaglutide vs tirzepatide — dose comparison across the incretin research class.
• GLP-1 research peptides — how the receptor class is studied across compounds.
• How to reconstitute GLP-1 peptides — step-by-step method and concentration maths.
• About our research lead — who reviews the analytical data behind every lot.